Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 4Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1

Interventions

Cyclophosphamide 222pembrolizumab 199Carboplatin 173Cisplatin 168Gemcitabine 167Paclitaxel 153Docetaxel 139Rituximab 137Bevacizumab 137Radiotherapy 136Dexamethasone 126Nivolumab 125Capecitabine 103fludarabine 102Pemetrexed 92fludarabine phosphate 91Fluorouracil 91Doxorubicin 85Oxaliplatin 79Etoposide 77Cytarabine 77Bortezomib 76Erlotinib Hydrochloride 74Leucovorin 72Filgrastim 68Lenalidomide 67Calcium Dobesilate 66Irinotecan 65atezolizumab 62Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Has results × paricalcitol × Clear all
NCT03519308 2024-03-15

A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

Abramson Cancer Center at Penn Medicine

Phase EARLY_PHASE1 Terminated
3 enrolled 13 charts
Gastrointestinal

Pancreatic Neoplasms

NCT00634582 2018-07-06

Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases

Wake Forest University Health Sciences

Phase 2 Terminated
2 enrolled 6 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡